OBT IO PIPELINE
Leveraging our unique IO discovery process, OBT is focused on:
PROPRIETARY IO DISCOVERY PROCESS
OBT's proprietary in-house IO target selection and validation process, which is instrumental in the development and POC of a never-before described cancer immune escape mechanism with wide-ranging therapeutic potential, is built upon:
OX001R/L
OBT has recently discovered a novel T cell modulatory axis, OX001R/L, which is involved in cancer immune escape independent of the PD1/PDL1 axis. Within just two years of this exciting new IO discovery, OX001R/L has reached in vivo POC. The program has yielded a therapeutic antibody candidate, OX001R/L, (Fig 1) that displays efficacy at least equipotent to Pemrolizumab in a humanized lung cancer model. OX001R/L is now entering IND enabling studies. Click here to learn more.
- Several IO and ADC development programs targeting solid tumours
- Building partnerships through bespoke IO discovery projects and IO target licensing.
PROPRIETARY IO DISCOVERY PROCESS
OBT's proprietary in-house IO target selection and validation process, which is instrumental in the development and POC of a never-before described cancer immune escape mechanism with wide-ranging therapeutic potential, is built upon:
- A cancer membrane protein library, with over 6500 membrane proteins
- A membrane protein library of tumour infiltrating lymphocytes (TILs) from lung, breast and colorectal patients
- Identification of novel receptors induced by T cell/tumour contact
- Identification of novel therapeutically targetable IO pathways in the TIL/cancer-cell-synapse space (click here to learn more)
- Validation of IO pathways in patient derived 3D tumour explants from the same tumours
- Profiling of target candidates in flow cytometry; immuno-histochemical analysis; functional assays and in vitro studies with tool antibodies
- Antibody generation across multiple antibody platforms for tool reagents and therapeutic leads
OX001R/L
OBT has recently discovered a novel T cell modulatory axis, OX001R/L, which is involved in cancer immune escape independent of the PD1/PDL1 axis. Within just two years of this exciting new IO discovery, OX001R/L has reached in vivo POC. The program has yielded a therapeutic antibody candidate, OX001R/L, (Fig 1) that displays efficacy at least equipotent to Pemrolizumab in a humanized lung cancer model. OX001R/L is now entering IND enabling studies. Click here to learn more.
OX003R
OBT has discovered and validated OX003R (AACR Abstract #5167 below), a novel co-stimulatory IO target, with high expression in tumor-derived lymphocytes, in a variety of solid tumor types, and in activated or exhausted T cells. Chimeric 1B3 is being developed as a promising therapeutic antibody with agonistic TIL activity, specifically in the tumor microenvironment. Our senior scientist, Angelo Kaplan, explains OX003R here.
OBT has discovered and validated OX003R (AACR Abstract #5167 below), a novel co-stimulatory IO target, with high expression in tumor-derived lymphocytes, in a variety of solid tumor types, and in activated or exhausted T cells. Chimeric 1B3 is being developed as a promising therapeutic antibody with agonistic TIL activity, specifically in the tumor microenvironment. Our senior scientist, Angelo Kaplan, explains OX003R here.
OBT ADC PIPELINE
OX001L
Our most advanced ADC is aimed at multiple solid cancer indications.
OX001L
Our most advanced ADC is aimed at multiple solid cancer indications.
OBT CO-DEVELOPMENT PIPELINE
OBT MENARINI CO-DEVELOPMENT PIPELINE
MEN1112
MEN1112 is a high affinity, defucosylated, humanized, monoclonal IgG1 antibody directed against human Bst1/CD157 antigen that is expressed with very high prevalence on blasts from patients with Acute Myeloid Leukaemia (AML). The antibody uses patients' innate immune cells to kill antigen-positive tumour cells by inducing Antibody Dependent Cell-mediated Cytotoxicity (ADCC). In vitro studies demonstrated MEN112 to promote efficient tumour cell killing through ADCC using AML cell lines. MEN1112 is currently completing a Phase I AML dose-escalation study - read more here.
MEN1309
MEN1309 is an antibody drug candidate constituted by a fully human IgG1 antibody directed against CD205 antigen inducing potent cytotoxic and anti-tumour activity. Extensive preclinical and translational data provided the proof of concept that MEN1309 is able to induce anti-tumour activity in vitro, in xenografts and in patient-derived xenograft models. MEN1309 is completing a Phase I trial in patients with CD205 positive solid tumours and NHL.
MEN1112
MEN1112 is a high affinity, defucosylated, humanized, monoclonal IgG1 antibody directed against human Bst1/CD157 antigen that is expressed with very high prevalence on blasts from patients with Acute Myeloid Leukaemia (AML). The antibody uses patients' innate immune cells to kill antigen-positive tumour cells by inducing Antibody Dependent Cell-mediated Cytotoxicity (ADCC). In vitro studies demonstrated MEN112 to promote efficient tumour cell killing through ADCC using AML cell lines. MEN1112 is currently completing a Phase I AML dose-escalation study - read more here.
MEN1309
MEN1309 is an antibody drug candidate constituted by a fully human IgG1 antibody directed against CD205 antigen inducing potent cytotoxic and anti-tumour activity. Extensive preclinical and translational data provided the proof of concept that MEN1309 is able to induce anti-tumour activity in vitro, in xenografts and in patient-derived xenograft models. MEN1309 is completing a Phase I trial in patients with CD205 positive solid tumours and NHL.
OBT PROGRAMS PARTNERED WITH BOEHRINGER INGELHEIM
Boehringer Ingelheim exercised two options between 2015 and 2016 for exclusive rights to targets discovered during our research collaboration using Oxford BioTherapeutics’ proprietary OGAP® system. Under the terms of the agreement, signed in 2013, Boehringer Ingelheim is responsible for the future development and commercialization of antibody products to both targets. Oxford BioTherapeutics will receive development and regulatory milestone payments, as well as royalties on any future product sales.
Boehringer Ingelheim exercised two options between 2015 and 2016 for exclusive rights to targets discovered during our research collaboration using Oxford BioTherapeutics’ proprietary OGAP® system. Under the terms of the agreement, signed in 2013, Boehringer Ingelheim is responsible for the future development and commercialization of antibody products to both targets. Oxford BioTherapeutics will receive development and regulatory milestone payments, as well as royalties on any future product sales.